Original Research Article

Profiling and Identification of the Metabolites of Evodiamine in Rats using Ultra–Performance Liquid Chromatography with Linear Ion Trap Orbitrap Mass Spectrometer

Fang Ping Wu, Yong Yang, Liang Hong Liu, Hong Pu, Ping Jin, Zu Fu Yao* and Wei Cai*

Dong Pharmaceutical Research of Hunan Key Laboratory, Hunan University of Medicine, Huaihua Hunan 418000, China

For correspondence: **Email: 623965021@qq.com, 20120941161@bucm.edu.cn, **Tel:** +86 745 2381253; **Fax:** +86 745 2381210*

Abstract

Purpose: To develop a highly sensitive and specific ultra-performance liquid chromatography with linear ion trap Orbitrap mass spectrometer (UPLC-LTQ-Orbitrap) method to profile and identify the metabolites of evodiamine in rats.
Methods: First, blood samples were collected after oral administration of evodiamine to rats (50 mg/kg). Next, the plasma samples were pretreated using a solid-phase extraction (SPE) method. Finally, all the samples were analyzed by ultra-performance liquid chromatography LTQ-Orbitrap mass spectrometry (UPLC-LTQ-Orbitrap) coupled with electrospray ionization source (ESI) in negative mode.
Results: A total of 7 metabolites (2 phase I and 4 phase II metabolites, including 4 new metabolites, viz, 10-hydroxyevodiamine sulfate, 10-hydroxyevodiamine sulfate, 10-hydroxyevodiamine glucuronide and 3-hydroxyevodiamine glucuronide) as well as the parent drug itself , were detected and identified based on accurate mass measurements, fragmentation patterns, and chromatographic retention times. The in vivo metabolic reactions of evodiamine in rats were hydroxylation, hydroxylation + sulfate conjugation, and hydroxylation + glucuronidation.
Conclusion: These results provide better understanding of the metabolism of evodiamine as well as strong indications of the effective forms of the drug in vivo.

Keywords: Evodiamine, Ultra–performance liquid chromatography with linear ion trap-Orbitrap, Hydroxyevodiamine sulfate, Hydroxyevodiamine glucuronide, Metabolites

INTRODUCTION

Evodiamine belonging to indoloquinazoline alkaloids, is a major constituent isolated from the herbal medicine *Evodia rutaecarpa* (Wu-zhu-yu), which has been officially listed in Chinese Pharmacopoeia [1] and widely used in China for more than 2000 years. Pharmacological studies indicate that it possesses variety of anti-thrombotic, anti-inflammatory, uterotonic, thermoregulatory, anti-obesity, hypotensive, and vasodilatory effects [2-5].

Previous reports demonstrated that evodiamine had low oral bioavailability in rats [6,7], which suggested that evodiamine might undergo an extensive first-pass metabolism. Pharmacological studies have revealed the

cytotoxicity of evodiamine might be related to the transformation of evodiamine into its 10-hydroxyevodiamine or other metabolites [8]. However, so far as we are aware, the biotransformation of evodiamine has not been fully investigated due to the limitations of analytical techniques [8-10]. For instance, only two and five metabolites were detected and identified *in vivo* and *in vitro*, respectively [8-11]. In this respect, it is important to characterize its metabolism profile *in vivo*, which can help to further understand the mechanism of action of evodiamine.

During the past decade, liquid chromatography/electrospray tandem mass spectrometry was the main method for the structural characterization of drug metabolites *in vivo* and *in vitro* [12,13]. Ultra–high performance liquid chromatography coupled with high–resolution mass spectrometer (UPLC-HRMS) such as UPLC-LTQ-Orbitrap significantly contributes to the characterization of drug metabolites due to its higher separation and resolution capacities in a shorter time [14,15].

The principal metabolic pathways of evodiamine in rats were proposed for the first time in this study. This study is also useful to understand the drug's pharmacological effects.


Figure 1: The structure of evodiamine

EXPERIMENTAL

Chemicals and reagents

Evodiamine was isolated from the 95 % aqueous ethanolic extract of Euodiae Fructus in our laboratory. Its structure was identified by comparing their UV, MS, ^{1}H-NMR and ^{13}C-NMR data with it's in the literature. Its purity was > 98 % by HPLC analysis. The structure is displayed in Figure 1. Grace PureTM SPE C18 phase extraction cartridges (200 mg/3 mL, 59 µm, 70 Å) were purchased from Grace Davison Discovery ScienceTM (Deerfield, IL, USA). Ultra-pure water used throughout the experiment was freshly prepared using a Milli-Q water purification system (Millipore, Billerica, MA, USA).

Acetonitrile was of HPLC-grade (Fisher, NJ, USA). All other chemicals and reagents were of analytical grade and commercially available.

Animals and drug administration

Six male Sprague-Dawley rats (weighing 200 – 250 g) were supplied by Beijing Weitong Lihua Experimental Animals Company (Beijing, China) and housed in controlled environmental conditions (temperature, 24 ± 2 °C; relative humidity, 70 ± 5 %) with free access to food and water in a week for acclimatization. The rats were randomly divided into two groups: Group A (n = 3), drug group for plasma; Group B (n = 3), control group for blank plasma. Before the experiment, all rats were fasted for 12 h and fed with water. Evodiamine was suspended in 0.5 % carboxymethylcellulose sodium (CMC-Na) aqueous solution. The rats from group A were anesthetized with ether at 2 h after oral administration of evodiamine at a dose of 100 mg/kg body weight and then sacrificed by decapitation. The rats from group B were oral administrated with 0.5 % CMC-Na aqueous solution in the same way. The blood were withdrawn in heparinized centrifuge tubes and centrifuged at 4000 rpm for 10 min to obtain the plasma. All plasma samples were stored at – 20 °C until other pretreatment and analysis. The animal experiments were carried out in accordance with the guidelines for Animal Experimentation of Hunan University of Medicine, and the protocols were approved by the Animal Biomedical Ethical Committee of Hunan University of Medicine (approval ref no. kj-dw-20150901-01) [16].

Sample preparation

All plasma samples were pretreated by a solid-phase extraction (SPE). An SPE cartridge was pretreated with 5 mL of water, 5 mL of methanol and 5 mL of water, successively. 1 mL sample of plasma was loaded, and allowed to flow through the SPE cartridge with gravity. The SPE cartridge was washed with 5 mL of water and 5 mL of methanol, successively. The methanol eluate was collected and evaporated to dryness under N_2 at room temperature. The residue was re–dissolved in 100 µL of acetonitrile/water (10:90, v/v) and centrifuged at 12,000 rpm at 4 °C for 30 min. A volume of 2 µL supernatant was injected into UPLC-LTQ-Orbitrap MS for analysis.

Instrumentation and conditions

All LC/MS analyses were performed on a Finnigan LTQ/Orbitrap (Thermo Electron, Bremen, Germany) coupled to an ESI source

(Thermo Electron, Bremen, Germany). A Waters ACQUITY BEH C18 column (2.1 × 100 mm i.d., 1.7 μm) was used for separation of the metabolites at room temperature and a flow rate of 0.3 mL/min. The mobile phase consisted of water (solvent A) and acetonitrile (solvent B) using a gradient elution as follows: 0 – 2 min, 5 % B; 2 – 3 min, 5 – 10 % B; 3 – 25 min, 10 – 35 % B; 25 – 30 min, 35 – 80 % B; 30 – 35 min, 80 % B; 35 – 36 min, 80 – 5 % B; 36 – 40 min, 5 % B.

Samples were analyzed in the negative mode with the tune method set as follows: sheath gas (nitrogen) flow rate of 30 arb, aux gas (nitrogen) flow rate of 5 arb, spray voltage of 4.0 kV, capillary temperature of 350 ℃, capillary voltage of 25 V, tube lens voltage of 110 V.

In the full scan experiment, resolution of the Orbitrap mass analyzer was set at 30,000 and with a mass range of m/z 100 – 800. Data-dependent MS/MS scanning was performed to minimize total analytical time as it can trigger fragmentation spectra of target ions. The collision energy for collision induced dissociation (CID) was adjusted to 30 % of maximum, and the isolation width of precursor ions was m/z 2.0 Da.

Peak selections and data processing

Thermo Xcaliber 2.1 workstation was used for the data acquisition and processing. In order to obtain as many fragment ions of the metabolites as possible, the peaks detected with intensity over 10,000 were selected for identifications. The chemical formulas for all parent ions of the selected peaks were calculated from the accurate mass using a formula predictor by setting the parameters as follows: C [0 – 30], H [0 – 50], O [0 – 20], S [0 – 4], N [0 – 4], Cl [0 – 4], and ring double bond (RDB) equivalent value [0 – 15]. Other elements such as P and Br were not considered because they are rarely present in the complex matrix.

RESULTS

Fragmentation pathway of evodiamine

In order to facilitate the structural identification of the metabolite, the MS^n fragmentation pattern of evodiamine was investigated [17]. The parent ion showed a deprotonated ion $[M-H]^-$ at m/z 302.1296 (2.8 ppm, $C_{19}H_{16}ON_3$) in negative mode. Fragmentation of the parent ion provided characteristic fragment ions at m/z 169.0765 (2.5 ppm, $C_{11}H_9N_2$) and m/z 142.0658 (4.7 ppm, $C_{10}H_9N$) by the loss of the moieties C_8H_7ON and

C_8H_7ON +CNH, respectively, which were useful information in metabolite identification. Besides, the fragment at m/z 142 can be formed by loss of CNH from the ion at m/z 169 in the MS^3 spectra. The MS^n spectrum of evodiamine was shown in Figure 2.

Detection and structural elucidation of metabolites

After comparison the high-resolution EIC (HREIC) of the drug samples with corresponding control samples, a total of 7 metabolites as well as the parent drug were detected and identified. The HREIC of drug sample is shown in Figure 3. The chromatographic and mass spectrometric data of the parent drug and its metabolites are shown in Table 1.

Metabolite M0

Metabolite M0 was unambiguously identified as evodiamine by comparing the retention time, accurate MS and MS/MS spectra with the authentic reference.

Metabolites M1 and M2

Metabolites M1 and M2 were eluted at 17.42 and 19.29 min with the quasi-molecular ions of m/z 318.1248 (3.6 ppm, $C_{19}H_{16}O_2N_3$) and m/z 318.1245 (2.6 ppm, $C_{19}H_{16}O_2N_3$), 16 Da more than that of evodiamine, indicating that it might be the product of mono-hydroxylated of the prototype drug. This ion at m/z 185 in M1 MS^2 spectra was found to be characterization for the presence of a hydroxyl group at one of the positions of the aromatic ring of the indole moiety. Based on these results, metabolite M1 were proposed to be mono-hydroxylated on the indole ring. This ion at m/z 169 in M2 MS^2 spectra belonged to the aromatic ring of the indole moiety, suggesting that metabolite M2 were proposed to be no mono-hydroxylated on the indole ring. Previous reports [11] showed that the metabolites 10-hydroxyevodiamine and 3-hydroxyevodiamine of evodiamine is easy to produce, therefore, M1 and M2 were tentatively identified as 10-hydroxyevodiamine and 3-hydroxyevodiamine, respectively.

Metabolites M3 and M4

Metabolites M3 and M4, possessing the same deprotonated molecular ion $[M–H]^-$ at m/z 398.0813 (2.0 ppm, $C_{18}H_{12}O_5N_3S$), were detected at 15.81, and 16.44 min, respectively. This fragment ion at m/z 318 was observed by

**Figure 2:** The MS[n] specturm of evodiamine

Figure 3: High-resolution EIC in 5 ppm for the multiple metabolites in rat plasma *m/z* 302.1288, 318.1237, 398.0805, and 494.1558

loss 80 Da than the precursor ion at m/z 398 in their MS^2 spectra, suggesting the presence of one sulfate residue in. The MS^3 of M3 and M4 possessed the same MS^2 spectra with M1 and M2, respectively, suggesting the core structure of M3 and M4 were mono-hydroxylated of evodiamine. Therefore, M3 and M4 were tentatively characterized as 10-hydroxyevodiamine sulfate and 3-hydroxyevodiamine sulfate, which were new metabolites.

Metabolites M5 and M6

Metabolites M5 and M6 were eluted at 12.19, and 12.68 min, with the quasi-molecular ions of m/z 494.1573 (3.2 ppm, $C_{25}H_{24}O_8N_3$), and m/z 494.1575 (3.4 ppm, $C_{25}H_{24}O_8N_3$). This characteristic ion at m/z 318 was observed by loss 176 Da than the precursor ion at m/z 494 in their MS^2 spectra, which indicated that they might be products of glucuronide conjugation of M1 and M2. Analyzing the clogP values of their potential metabolites, M5 and M6 were tentatively assigned as 10-hydroxyevodiamine Sulfate and 3-hydroxyevodiamine sulfate, which were new metabolites.

Proposed metabolic pathways of evodiamine

In this study, 7 metabolites (4 new) as well as parent drug itself were detected in the plasma. The proposed major metabolic pathways of evodiamine in the rat plasma are demonstrated in Figure 4. In general, the metabolism of evodiamine *in vivo* was firstly undergone hydroxylation metabolic reactions (M1–M2), and then sulfate conjugation (M3–M4) and glucuronide conjugation (M5–M6) were taken place on the position of hydroxyl groups.

DISCUSSION

An UPLC-LTQ-Orbitrap mass spectrometry method for analysis the metabolites of evodiamine was established at first. In order to obtain an appropriate elution system, mobile systems such as acetonitrile – water and methanol – water were tested. The result demonstrated that acetonitrile – water with a gradient elution mode could afford better resolution of chromatographic peaks among the metabolites and endogenous components.

The evodiamine metabolites under investigation belong to indoloquinazoline alkaloids, which make it predestined detection by ESI in positive mode. However, Negative mode was selected for ESI-MS analysis in this study, as it provided more intensity response and less mass spectral interference [16]. To our best knowledge, the biotransformation of evodiamine has been poorly understood, although some works on the metabolism of evodiamine have already been performed [8–11]. For example, only one and two metabolites were unambiguously identified from


Figure 4: Proposed major metabolic pathway of evodiamine in rats

Table 1: Details of evodiamine metabolites in rat plasma

Peak	t_R	Theoretical mass (*m/z*)	Experimental mass (*m/z*)	Error (ppm)	Formula [M-H]$^-$	MS/MS fragment	Identification
M0	26.05	302.1288	302.1296	2.8	$C_{19}H_{16}ON_3$	MS^2 [302]: 169(100), 142(5) MS^3 [169]: 142(100),116(14),154(4)	evodiamine
M1	17.42	318.1237	318.1248	3.6	$C_{19}H_{16}O_2N_3$	MS^2 [318]: 185(100), 158(15)	10-hydroxyevodiamine
M2	19.29	318.1237	318.1245	2.6	$C_{19}H_{16}O_2N_3$	MS^2 [318]: 169(100), 142(8)	3-hydroxyevodiamine
M3	15.81	398.0805	398.0813	2.0	$C_{19}H_{16}O_5N_3S$	MS^2 [398]: 318(100) MS^3 [318]: 185(100), 158(8)	10-hydroxyevodiamine Sulfate
M4	16.44	398.0805	398.0813	2.0	$C_{19}H_{16}O_5N_3S$	MS^2 [398]: 318(100) MS^3 [318]: 169(100)	3-hydroxyevodiamine Sulfate
M5	12.19	494.1558	494.1575	3.4	$C_{25}H_{24}O_8N_3$	MS^2 [494]: 318(100),175(22)	10-hydroxyevodiamine Glucuronide
M6	12.68	494.1558	494.1573	3.2	$C_{25}H_{24}O_8N_3$	MS^2 [494]: 318(100),175(42)	3-hydroxyevodiamine Glucuronide

urine and feces of SD rats by comparing the retention time and mass spectrometry of metabolites from Microbial biotransformation [8,11]. Five metabolites were tentatively detected and characterize in human liver microsomes. It is worth mentioning that none metabolites was detected in rat plasma including parent drug. In our study, 7 metabolites including parent drug itself were detected and identified in rat plasma. However, the previously reported metabolite named N-demethylated evodiamine was undetected in both positive and negative MS modes in the present experiment, which might be because the species of experiment was different.

CONCLUSION

By online LC-MS^n data acquisition and offline data processing methods of the software Xcalibur 2.1, a total of 7 metabolites were detected and identified based on accurate mass measurements, the fragmentation patterns and chromatographic retention times. The findings show that the profile of the metabolites of evodiamine in rats can provide greater insight into its pharmacological effects, metabolic fate *in vivo*, and bioactive components.

ACKNOWLEDGEMENT

REFERENCES

1. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China, vol.1 China Medical Science Press, Beijing, China; 2010; p 160.
2. Chiou WF, Chou CJ, Shum AYC, Chen CH. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 1992; 215(2): 277-283.
3. Yu H, Jin H, Gong W, Wang ZL, Liang HP. Pharmacological actions of multi-target-directed evodiamine. Molecules 2013; 18(2): 1826-1843.
4. Tsai TH, Lee TF, Chen CF, Wang LCH. Thermoregulatory effects of alkaloids isolated from Wu-chu-yu in afebrile and febrile rats. Pharmacol Biochem Behav 1995; 50(2): 293–298
5. Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 2001; 67(7): 628–633
6. Komatsu K, Wakame K, Kano Y. Pharmacological properties of Galenical preparation. XVI. Pharmacokinetics of evodiamine and the metabolite in rats. Biol Pharm Bull 1993; 16(9): 935–938.
7. Shyr MH, Lin LC, Lin TY, Tsai TH. Determination and pharmacokinetics of evodiamine in the plasma and feces of conscious rats. Anal Chim Acta 2006; 558(1): 16-21.
8. Li L, Liu R, Ye M, Hu XY, Wang Q, Bi KX, Guo DA. Microbial metabolism of evodiamine by Penicillium janthinellum and its application for metabolite identification in rat urine. Enzyme Microb Technol 2006; 39(4): 561–567.
9. Jan WC, Lin LC, Don MJ, Chen CF, Tsai TH. Elimination of rutaecarpine and its metabolites in rat feces and urine measured by liquid chromatography. Biomed Chromatogr 2006; 20(11): 1163-1171.
10. Sun HZ, Fang ZZ, Cao YF, Sun XY, Hong M. Investigation of the in vitro metabolism of evodiamine: characterization of metabolites and involved cytochrome p450 isoforms. Phytother Res 2013; 27(5): 705-712.
11. Li L. Metabolic studies of ecodiamine, rutaecarpine and L-teterahydropalamatine in microbial organisms and rats. [Dissertation]. [Shenyang]: Shenyang Pharmaceutical University, 2005; pp 87-95.
12. Wani TA, Zargar S. New Highly-Sensitive Ultra-Performance Liquid Chromatography-Mass Spectrometry Method for Quantification of Telmisartan in Human Plasma [J]. Trop J Pharm Res 2015, 14(3): 511-518.
13. Beaudry F, Yves Le Blanc JC, Coutu M, Ramier I, Moreau JP, Brown NK. Metabolite profiling study of propranolol in rat using LC/MS/MS analysis. Biomed Chromatogr 1999, 13(5): 363-369.
14. Zhang J, Cai W, Zhou Y, Liu Y, Wu XD, Li Y, Lu JQ, Qiao YJ. Profiling and identification of the metabolites of baicalin and study on their tissue distribution in rats by ultra–high–performance liquid chromatography with linear ion trap–Orbitrap mass spectrometer. J Chromatogr B 2013; 985: 91−102
15. Ni SM, Qian DW, Duan JA, Guo JM, Shang EX, Shu Y, Xue CF. UPLC–QTOF/MS-based screening and identification of the constituents and their metabolites in rat plasma and urine after oral administration of Glechoma longituba extract. J Chromatogr B 2010, 878(28): 2741-2750.
16. Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals. Vol. 1. No. 2. Ottawa: Canadian Council on Animal Care, 1993.
17. Gao P, Wang LZ, Wu RG, Han J, Wang CY, Tang SM, Liu YG. Esi-ion-trp MS study on fragmentation pathways of evodiamine and rutecarpine. Chin J Pharm Anal 2012, 32(5): 772-774.